Felicia Adaobi Ikolo

Dr. Felicia Adaobi Ikolo

Biochemistry, Genetics and Molecular Biology, St. George's University, Saint George's, Grenada
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 December 2016 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
PKPaul Kruszka
Paul Kruszka
APAntonio R. Porras
Antonio R. Porras
ASAndrew K. Sobering
Andrew K. Sobering
Felicia Adaobi IkoloFelicia Adaobi Ikolo
Felicia Adaobi Ikolo
SQSamantha La Qua
Samantha La Qua
MMMaximilian Muenke
Maximilian Muenke

17 December 2020 in Molecular Genetics & Genomic Medicine
Verified
Journal Article
Open access
PDF file
AGAlyssa Grygiel
Alyssa Grygiel
Felicia Adaobi IkoloFelicia Adaobi Ikolo
Felicia Adaobi Ikolo
RSRaphielle Stephen
Raphielle Stephen
DBDawnell Bleasdille
Dawnell Bleasdille
PRPatricia Robbins‐Furman
Patricia Robbins‐Furman
SESarah H. Elsea
Sarah H. Elsea
Background: Grenada is a small, resource‐limited Caribbean country with a high incidence of sickle cell disease (SCD). Since little is known about the challenges facing individuals living with SCD in the West Indies, we sought to assess barriers to healthcare and the impact of SCD on quality of life in Grenada.Methods: Both adults aged 18+ (n = 19) and caregivers of children aged 2–17 (n = 26) completed validated survey measures regarding barriers to care and quality of life, along with a genetics knowledge questionnaire. Caregivers also completed a caregiver burden scale. Survey scores were calculated, and responses were analyzed for an association between demographic variables.Results: The Barriers to Care Questionnaire, in which lower scores indicate more barriers, revealed that both adults (mean = 69.9) and children (mean = 75.5) with SCD experienced reduced access to care. The Adult Sickle Cell Quality of Life Measurement Information System indicated increased depression and loneliness in adults, with the lowest scores in the Emotional subscale. However, the Pediatric Quality of Life Inventory answered by caregivers of children with SCD showed the lowest scores in the Physical Functioning subscale. Further analysis using the Caregiver Burden Scale‐Zarit Burden Interview revealed that 53.8% of caregivers of children with SCD indicated “little to no burden,” which may reflect a difference in cultural expectations of a caregiver between high‐income countries and Grenada. Finally, ~80% of respondents knew that SCD was a genetic condition; however, 61%–84% could not correctly indicate recurrence risks, demonstrating a need for additional education.Conclusion: These data provide new insights regarding the experience of living with SCD in Grenada and support the need for further investigations into specific barriers to healthcare delivery, which could also improve education and well‐being for those affected by SCD in Grenada and in the broader Caribbean community.

8 October 2015 in Molecular BioSystems
Verified
Journal Article
Open access
PDF file
Felicia Adaobi IkoloFelicia Adaobi Ikolo
Felicia Adaobi Ikolo
MZMeng Zhang
Meng Zhang
DHDean J. Harrington
Dean J. Harrington
CRCarl Robinson
Carl Robinson
AWAndrew S. Waller
Andrew S. Waller
GBGary Black
Gary Black
Peptidyl-prolyl isomerase (PPIase) lipoproteins have been shown to influence the virulence of a number of Gram-positive bacterial human and animal pathogens, most likely through facilitating the folding of cell envelope and secreted virulence factors. Here, we used a proteomic approach to demonstrate that the Streptococcus equi PPIase SEQ0694 alters the production of multiple secreted proteins, including at least two putative virulence factors (FNE and IdeE2). We demonstrate also that, despite some unusual sequence features, recombinant SEQ0694 and its central parvulin domain are functional PPIases. These data add to our knowledge of the mechanisms by which lipoprotein PPIases contribute to the virulence of streptococcal pathogens.

18 April 2024
Verified
Book Chapter
Open access
PDF file
Felicia Adaobi IkoloFelicia Adaobi Ikolo
Felicia Adaobi Ikolo
SMSabyasachi Maity
Sabyasachi Maity
RFRobert Finn
Robert Finn
AAAtoum Abdullah
Atoum Abdullah
ATAlireza Tajik
Alireza Tajik
MMMary Maj
Mary Maj
Animal models of genetic disorders that have risen due to selective breeding can be used as a valuable model to teach the basic concepts of population genetics. The Clumber Spaniel is a breed of dog created in the mid-1700s by the 4th Duc du Noailles. He selectively bred this dog for the elderly gentleman. This sleepy-looking breed survives today, though 1% suffer from severe exercise intolerance due to an autosomal-recessive founder mutation in the pyruvate dehydrogenase phosphatase 1 (PDP1) gene. PDP1 deficiency was long suspected to be a human metabolic disorder and described at the molecular level in 2005 by Robinson and coworkers. The Robinson group later identified a founder mutation within the PDP1 gene of the Clumber spaniel. This case clearly illustrates how a detrimental mutant allele in a small population, when selecting for phenotype, can persist in the progeny of that group. In this review, we discuss the origin of the “Founder Effect” theory and present an example of how a bottleneck that occurred during the selective breeding of the Clumber spaniel over 250 years ago led to the current genetic status of the breed. Today, genotyping can help reduce the incidence of PDP1 in the Clumber breed.

22 July 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
BIBawo Ikolo
Bawo Ikolo
MOMathew Oyelami
Mathew Oyelami
OMOdinaka Emmanuel Mgbeke
Odinaka Emmanuel Mgbeke
KJKwami Jones
Kwami Jones
STShellon Thomas
Shellon Thomas
Felicia Adaobi IkoloFelicia Adaobi Ikolo
Felicia Adaobi Ikolo
Sickle Cell Disease (SCD) is a hereditary hemoglobinopathy arising from a single-nucleotide transversion (GAG → GTG) at codon six of the HBB gene on chromosome 11, substituting glutamic acid with valine in the β-globin chain and producing hemoglobin S (HbS). Under hypoxic conditions, HbS polymerizes and distorts erythrocytes into the characteristic sickle shape, initiating a cascade of vaso-occlusion, chronic hemolytic anemia, and progressive multi-organ damage that defines the clinical burden of this disease. Although SCD has ancient origins in sub-Saharan Africa, the Indian subcontinent, the Middle East, and the Mediterranean, regions where it conferred heterozygous resistance to malaria, the ease of human migration has long since made it a global health concern, affecting an estimated 300,000–400,000 newborns annually. Advances in molecular and genomic research have deepened our understanding of SCD pathophysiology, revealing the central contributions of hemoglobin polymerization, oxidative stress, endothelial inflammation, and nitric oxide depletion to disease progression. Current management rests on supportive pharmacological interventions, including hydroxyurea, chronic transfusion therapy, L-glutamine, and multimodal pain management, complemented by lifestyle modifications. Curative approaches have advanced substantially: hematopoietic stem cell transplantation (HSCT) remains the established standard of cure, while the regulatory approvals in late 2023 of the CRISPR/Cas9-based exagamglogene autotemcel (Casgevy) and the lentiviral vector-based lovotibeglogene autotemcel (Lyfgenia) represent the most transformative development in the history of SCD therapeutics. This review traces the disease from its ancient origins and molecular characterization through to its clinical manifestations, inheritance patterns, screening strategies, and the full spectrum of current and emerging therapies. Persistent challenges, prohibitive treatment costs, healthcare inequities, the ethical dimensions of genome editing, and the urgent need for long-term safety data, are examined critically, with a view to informing the research and policy agenda that must accompany these remarkable scientific advances.

27 July 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
KSKanwarjot Singh
Kanwarjot Singh
DMDervens Kidder Michaud
Dervens Kidder Michaud
TPTal Parness
Tal Parness
OMOdinaka Emmanuel Mgbeke
Odinaka Emmanuel Mgbeke
HOHenry Okodaso
Henry Okodaso
Felicia Adaobi IkoloFelicia Adaobi Ikolo
Felicia Adaobi Ikolo
Sickle cell disease (SCD) is a monogenic hemoglobinopathy in which hemoglobin S (HbS) polymerizes on deoxygenation, leading to sickling of red blood cells (RBCs) and driving the acute vaso-occlusive crisis (VOC). With curative (transformative) therapies inaccessible to most patients in sub-Saharan Africa and the Caribbean, where burden is highest, optimizing acute VOC care is a priority; yet oxygen is given reactively, after hypoxemia is documented, not at symptom onset when polymerization is most interruptible. We conducted a structured narrative review integrating HbS polymerization kinetics, clinical studies of oxygen-based therapies, trial protocols, and home-care implementation evidence (PubMed, Scopus, Google Scholar; 1974–2026). When RBCs release oxygen, HbS does not solidify at once: a brief pause, the nucleation delay phase (tD), precedes polymerization and sickling. Because tD falls steeply as deoxygenated hemoglobin rises (inversely, to its ~30th–50th power), a small early gain in oxygen saturation (~5–10%) lengthens it many-fold, opening a short window, roughly 30 min from onset, during which oxygen may abort a crisis. The clinical message is that timing, not dose, is decisive: oxygen at the first symptoms may prevent a crisis that the same oxygen, given later, cannot. Standard, high-flow, hyperbaric, and inhaled nitric-oxide modalities help in selected hospital settings, and the DREPADOM model shows community delivery before hospital arrival is feasible and safe. The central argument is precision in timing, not quantity: starting oxygen at symptom onset could turn a low-cost, universally available treatment into a crisis-aborting one for patients beyond the reach of curative therapy. We advance this as a mechanistically grounded but clinically untested hypothesis; regional implementation trials in the Caribbean and sub-Saharan Africa are urgently warranted.